SOUTH SAN FRANCISCO, Calif., Oct. 9, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announces selection of a Werner Helicase Inhibitor Development Candidate (DC) and Investor R&D Day.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.